Our Pipeline
Our Pipeline consists of three group of products, with multiple potential candidates:
- NewroBus: Nano-size, single-chain antibodies carrying biologics through the Blood-Brain Barrier (BBB)
- TNF-α Inhibitors: potent, TNF-α inhibitors nano antibodies (TNFI)
- Alzheimer’s Disease Candidate: Hetero-trimer molecules consisting of one NewroBus molecule linked to two molecule of TNF-α inhibitors
NewroBus
Nano-size, single-chain antibodies that can carry biologics through the Blood-Brain Barrier. Four compounds have been selected from a large pool of potential candidates based on their ability to cross BBB without interfering with Tf binding and uptake, and also based on humanness, specificity, BBB permeability and tolerability. NewroBus compound are versatile and can be used to carry different biologics across the BBB.
NN-101
NN-102
NN-103
NN-104
NewroBus for the brain: humanized TfR1-targeting nanobodies with high BBB permeability and cargo transport capacity
Tao Yin, Metin Yesiltepe, Sanjay Metkar, Aubin Ramon, Matthew Greenig, Pietro Sormanni, Luciano D’Adamio
Source: bioRxiv (2020)
TNF-α inhibitors
Two potent, TNF-α inhibitors nano-antibodies (TNFI) have been developed to be used in conjunction with NewroBus technology to treat Alzheimer’s disease and other neurodegenerative diseases where TNF-α plays a pathogenic role. These TNFI do not cross the BBB by themselves.
NN-223
NN-224
Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseases
Tao Yin, Aubin Ramon, Matthew Greenig, Pietro Sormanni, Luciano D’Adamio
Source: bioRxiv
Alzheimer’s Disease Candidate
Our lead product for the treatment of Alzheimer’s Disease is NN-841, a hetero-trimer consisting of one molecule of NewroBus NN-103 linked to two molecules of TNF-α inhibitors NN-224.
NN-841
